Worth reading
45Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
200000
Potential shares (common stock)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Partial transfer of previously issued Series 1 Stock Acquisition Rights (transfer between stock acquisition rights holders)
Who receives how much
Equivalent to 200,000 shares (2,000 stock acquisition rights)
Uehara Yuji (上原祐司) (2,000 rights, equivalent to 200,000 shares)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
No change
Terms of the stock acquisition rights
Exercise price
¥2,295 per share; fixed exercise price, with no adjustment to the exercise price
Exercise period
From 16 December 2025 to 15 December 2027
Number of Stock Acquisition Rights
Total issued: 21,000 rights; unexercised balance: 15,375 rights (after this transfer)
Intended allottee's holding policy
For pure investment purposes. The policy is to exercise the rights in stages, taking the market price and trading volume into consideration. The shares acquired through exercise are expected to be sold to recover the funds.
Procedures under the Corporate Code of Conduct
Approval by written resolution in lieu of a board resolution (Article 370 of the Companies Act)
Most recent equity financing
Series 1 Stock Acquisition Rights issued on 15 December 2025 through a third-party allotment: 21,000 rights, total issue value of ¥32,130,000, and ¥4,819,500,000 to be raised through exercise
Impact on Business Performance
This transfer will have no impact on the company's results.
| Item | Details |
|---|---|
| Type of issuance or disposal | Partial transfer of previously issued Series 1 Stock Acquisition Rights (transfer between stock acquisition rights holders) |
| Number of shares to be issued or disposed of | Equivalent to 200,000 shares (2,000 stock acquisition rights) |
| Intended allottee | Uehara Yuji (上原祐司) (2,000 rights, equivalent to 200,000 shares) |
| Intended allottee's holding policy | For pure investment purposes. The policy is to exercise the rights in stages, taking the market price and trading volume into consideration. The shares acquired through exercise are expected to be sold to recover the funds. |
| Total number of issued shares | No change |
| Exercise price | ¥2,295 per share; fixed exercise price, with no adjustment to the exercise price |
| Exercise period | From 16 December 2025 to 15 December 2027 |
| Number of Stock Acquisition Rights | Total issued: 21,000 rights; unexercised balance: 15,375 rights (after this transfer) |
| Procedures under the Corporate Code of Conduct | Approval by written resolution in lieu of a board resolution (Article 370 of the Companies Act) |
| Most recent equity financing | Series 1 Stock Acquisition Rights issued on 15 December 2025 through a third-party allotment: 21,000 rights, total issue value of ¥32,130,000, and ¥4,819,500,000 to be raised through exercise |
| Impact on Business Performance | This transfer will have no impact on the company's results. |
Items this document does not state (17)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateDilution RateBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As it had become difficult for Ucapi to continue exercising the rights at the same pace as before, the company determined that it would be beneficial to bring in a new stock acquisition rights holder in order to spread the exercise opportunities and raise funds steadily and flexibly while taking market conditions into consideration.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.